https://www.transhumancapital.com/philosophy daily 1.0 2024-12-11 https://www.transhumancapital.com/crsincock daily 0.75 2024-12-19 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/485add4b-8fbc-4d16-9232-5a1528ea803e/C.R.+Sincock+2023.jpg CR Sincock - C.R. Sincock II Managing Partner C.R. Sincock, II, graduated magna cum laude as a member of Phi Beta Kappa from Harvard College in 2007 with an A.B. in economics. He was chairman of the Harvard Political Union, John Harvard Scholar and a winner of the Exposé Writing Award. After graduation, Sincock joined the energy desk at QVT Financial LP, a multi-strategy hedge fund based in New York City. He pursued advanced coursework in abstract and applied mathematics at Columbia University and Harvard University before entering Harvard Business School, graduating in 2013 as a Baker Scholar with an M.B.A. in general management. Sincock subsequently joined Avfuel Corporation, a global supplier of aviation fuel and services with sales in excess of $2 billion in revenue, where he is now executive vice president and a member of the board of directors. He was later named president and CEO of Avfuel’s sister company, Avflight, which owns and operates FBOs and other infrastructure at 31 airports around the world. In 2014, Sincock founded Transhuman Capital, a venture firm focused on investments in hard science that solve the biggest problems of humanity. Later that same year, he completed the firm’s first investment in the seed round of Roivant Sciences and added to the position in several follow-on rounds. In 2019, he led the seed round for Kriya Therapeutics and subsequently made significant investments in follow-on rounds. He served on the Board of Directors at Kriya Therapeutics for three years and now holds the position of Founding Investor and Senior Strategic Advisor. https://www.transhumancapital.com/media daily 0.75 2024-12-11 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/008e6f23-e52c-45e7-a459-46d31caeed56/whiteArtboard+3.png Media - Response begins enrollment for trial of RDX-002 for weight management Oct. 18, 2024 Response Pharmaceuticals has initiated subject enrolment for a Phase II trial of its drug candidate RDX-002, designed to manage weight rebound in patients ceasing treatment with Glucagon-like peptide 1 (GLP-1) agonists. The drug candidate aims to reduce post-prandial triglyceride levels and improve cardiometabolic risk factors. RDX-002 is a potent, selective and gut-specific inhibitor of intestinal microsomal triglyceride transfer protein (iMTP). By inhibiting iMTP, RDX-002 reduces the absorption of triglycerides and cholesterol post-meal, potentially aiding in weight management and cardiometabolic health. The drug is also being considered for patients on antipsychotic medication. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589555346029-UVJ7BYEKCQ4Q29HBJQOZ/Investments-08.jpg Media - Biotech Firm Targets Big Pharma With Drug-Tweak Patent Strategy July 3, 2024 A neuroscientist-led startup is borrowing a page from Big Pharma’s playbook, taking advantage of drug-approval shortcuts while securing advancements in psychiatric treatments—including in the growing psychedelics industry—before larger companies get there. Terran Biosciences Inc., a self-described “biotech platform company,” develops therapeutics and technologies for patients with neurological and psychiatric disorders. Terran’s goal is to patent secondary drug advances before the original drugmaker, upending the “patent thicket” strategy major pharmaceutical companies use to block competing medication. The approach is aimed at speeding the availability of improved treatment options for patients with chronic neurological and psychiatric ailments, but critics warn of the potential problems a glut of secondary patents may bring. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/0b271eca-3d7c-4fb3-9e03-3e91004678a5/whiteArtboard+6.png Media - Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion Oct. 23, 2023 Roche ROG 0.63%increase; green up pointing triangle Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences ROIV -1.36%decrease; red down pointing triangle, a company started by Republican presidential candidate Vivek Ramaswamy, and Pfizer PFE -0.10%decrease; red down pointing triangle in a deal worth more than $7 billion. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/70bfc8db-9b95-4620-88e3-bb7eded7f3e6/whiteArtboard+7.png Media - Kriya Announces More Than $430 million Series C Financing Round July 26, 2023 Cooley advised Kriya, a biopharmaceutical company, on the addition of over $150 million in capital committed as part of its Series C financing, bringing the total Series C financing round to more than $430 million. Since its founding in October 2019, Kriya has raised over $600 million in committed capital – and with this financing, Kriya’s cash runway is anticipated to run into late 2026. Lawyers Lauren Creel, Lindsy Solanki and Kristina Krasnikova led the Cooley team. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1621615363571-3Q4FM7V7992IE0CODU53/Bond+Biosciences+Logo.jpg Media - Bond Biosciences Announces the Closing of a Series B Financing January 25, 2022 Bond Biosciences, Inc. is a privately held biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions in the gastrointestinal (GI) tract to treat or prevent human disease. “The closing of our Series B financing will strengthen the development program for BBI-001 and advance our pipeline of non-absorbed, oral therapies” Bond’s clinical lead, BBI-001, an investigational new drug, is a non-absorbed oral therapeutic designed to bind dietary iron and inhibit iron absorption in patients that suffer from iron overload. Patients with excess iron in their body have a higher risk of liver diseases, certain cancers, joint pain, and metabolic diseases. BBI-001 will be initially developed to treat iron overload associated with Hereditary Hemochromatosis (HH), a genetic disorder that results in the over-absorption of dietary iron. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/eec419d9-5034-48c5-bd2b-1789fc64ac6c/whiteArtboard+6+copy+4.png Media - Gilead hopes to evoke ideas for new autoimmune treatments with $659M deal January 3, 2023 Gilead plans to work with EVOQ Therapeutics to hopefully bring to mind new treatments for autoimmune disorders in a deal worth up to $658.5 million. The two companies have signed a new licensing deal to work on preclinical development for rheumatoid arthritis and lupus. Gilead has gained the exclusive right to license EVOQ’s NanoDisc technology to develop the autoimmune candidates. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1627926826848-RW60MFJLE2CYLLV1SG09/Investments-03.jpg Media - Kriya Therapeutics Raises $100 Million To Bring Gene Therapy To The Masses July 14, 2021 Over the past several years, breakthroughs in gene therapy have led to treatments for rare diseases that were deadly just a decade ago. Take Zolgensma—in 2019, it was the first gene therapy approved by the FDA to treat spinal muscular atrophy, a rare genetic disease that affects the mobility of infants and children. But gene therapies have historically had two drawbacks: They are only used for rare diseases, and they carry a hefty price tag (treatment with Zolgensma costs $2.1 million). https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589232852702-047086OK7SEZG3NDSQRR/Investments-06.jpg Media - Roivant Sciences Strikes SPAC Deal Valuing The Drug Company At $7.3 Billion May 3, 2021 Seven years ago, Vivek Ramaswamy created Roivant Sciences with the aim of finding a new financial model for drug development. On Monday, Roivant Sciences announced it would be going public by merging with a special acquisition company in a deal that values Roivant at $7.3 billion. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1621617020334-JH4E2F2E0PBP50P0IW08/DVANT+Temp+logo.jpg Media - Ann Arbor cancer drug startup aims to start human testing, gets $1.2 million seed round April 12, 2021 A recent spin-out company from the University of Michigan aims to commercialize a new kind of cancer drug that could, down the road, help patients live longer. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589305309199-550F42YVYOLL1J5TM7VI/Investments-03.jpg Media - Taking gene therapy to the masses with innovations in diabetes, Alzheimer's and more March 30, 2021 When Kriya Therapeutics raised $80.5 million in a series A funding round last May, it was as clear a sign as any that gene therapy is moving beyond rare diseases and going mainstream. The biotech is working on three gene therapies to treat metabolic diseases, including its lead asset, KT-A112, for Type 1 diabetes. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589232852702-047086OK7SEZG3NDSQRR/Investments-06.jpg Media - Roivant Sciences to absorb Silicon Therapeutics with $450M-plus deal Feb 26, 2021 Roivant Sciences has moved to take molecule designer Silicon Therapeutics underneath its corporate umbrella in a deal worth $450 million or more that will merge its computational physics work with the efforts of its VantAI drug discovery outfit. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589232852702-047086OK7SEZG3NDSQRR/Investments-06.jpg Media - Ex-Myovant chief Seely makes way for Amgen alum Marek as company gears up for Orgovyx launch Feb 26, 2021 On the heels of its first approval, Myovant Sciences is tapping a new CEO to take that drug to market while stoking its R&D engine to find its successors. Dave Marek takes over from Lynn Seely, M.D., the company’s chief since June 2016. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589305309199-550F42YVYOLL1J5TM7VI/Investments-03.jpg Media - Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases May 12, 2020 Kriya Therapeutics announced today that it has raised $80.5 million in a Series A financing to fund the development of transformative gene therapies for highly prevalent serious diseases. Kriya was formed in the fourth quarter of 2019 and has an industry-leading gene therapy team that includes former senior leadership from Spark Therapeutics, AveXis, Sangamo Therapeutics, and other gene therapy companies. Kriya's pipeline today includes multiple AAV-based gene therapies for the treatment of type 1 and type 2 diabetes, severe obesity, and other indications. The company is located in the Bay Area, California and Research Triangle Park, North Carolina, and is building a platform infrastructure in partnership with leading academic institutions and industry pioneers.. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589305309199-550F42YVYOLL1J5TM7VI/Investments-03.jpg Media - Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases May 12, 2020 Kriya Therapeutics announced today that it has raised $80.5 million in a Series A financing to fund the development of transformative gene therapies for highly prevalent serious diseases. Kriya was formed in the fourth quarter of 2019 and has an industry-leading gene therapy team that includes former senior leadership from Spark Therapeutics, AveXis, Sangamo Therapeutics, and other gene therapy companies. Kriya's pipeline today includes multiple AAV-based gene therapies for the treatment of type 1 and type 2 diabetes, severe obesity, and other indications. The company is located in the Bay Area, California and Research Triangle Park, North Carolina, and is building a platform infrastructure in partnership with leading academic institutions and industry pioneers.. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589232392894-C4LPK94NHZ4RMROC32F0/Investments-06.jpg Media - Leading Healthcare Companies Announce COVID-19 Research Database April 21, 2020 SAN FRANCISCO, April 21, 2020 / PRNewswire — A consortium of leading healthcare companies today announced the launch of the COVID-19 Research Database, a secure repository of HIPAA-compliant, de-identified and limited patient-level data sets made available to public health and policy researchers to extract insights to help combat the COVID-19 pandemic. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589241192313-1RAFTQO39LNZWMFFRT7Z/Investments-06.jpg Media - Sumitovant Biopharma Created and Launched as Sumitomo Dainippon Pharma and Roivant Sciences Close Transaction for Strategic Alliance December 30, 2019 Sumitovant Biopharma Ltd. was today unveiled as a new, global biopharmaceutical company through the closing of the transaction previously announced on October 31, 2019 between Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, and Roivant Sciences, a technology-enabled healthcare company. https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589240837773-23P8B5U3MRB8R83U3NYU/Investments-07.jpg Media - Cincinnati Business Courier: P&G pitch contest won by inventor of device to ease pain January 15, 2020 Procter & Gamble Co.’s second-annual pitch contest was won by Richard Hanbury, CEO of Sana Health, who invented a wearable neurowave-stimulation device designed to control chronic pain. The P&G Ventures arm of the Cincinnati-based maker of consumer goods such as Kytta ointment to soothe pain in muscles, joints and the back (NYSE: PG) sponsored the so-called Innovation Challenge. https://www.transhumancapital.com/team daily 0.75 2020-05-11 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589234621738-E1V9JAAXYUHXYVD89647/AVFUEL%2BNBAA19%2BVEGAS%2B5541.jpg Team https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589234721534-BNC33WA5H5LRQPYZ4I2F/crs_photo.jpg Team https://www.transhumancapital.com/team-1 daily 0.75 2020-05-11 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589234621738-E1V9JAAXYUHXYVD89647/AVFUEL%2BNBAA19%2BVEGAS%2B5541.jpg Team (Copy) https://www.transhumancapital.com/contact daily 0.75 2020-05-11 https://www.transhumancapital.com/about daily 0.75 2024-12-11 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/b78c234e-f9eb-48f6-b517-0831c878d91c/C.R.+Sincock+2023.jpg Team - C.R. Sincock II Managing Partner https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1598638853469-VXR61F8NMW5T8EXBWA02/IMG-8055.jpg Team - Vincent Alessi Venture Partner Applied AI R&D / Product Lead, Forbes 30u30 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1598638818627-9Y9T3BBRM46XE71RQ75Z/DavidMiller Team https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1598634859410-GEB20PNYK9YEJ6VQ5A3R/RadOncolHds13d1%28116%29.JPG Team https://www.transhumancapital.com/craig-r-sincock daily 0.75 2020-05-11 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589233633169-M7U55I8L8N31R1CG9OV4/crs_photo.jpg Craig R. Sincock - Craig R. Sincock Managing Partner Craig R. Sincock acquired Avfuel Corporation in 1983. Under his leadership, the company has grown from a regional fuel supplier to its current position as a leading independent global supplier of aviation fuel and services. Mr. Sincock accomplished this growth through a strategic mix of 28 acquisitions (four of which were aviation divestitures from publicly traded energy companies), internal sales growth and marketing alliances. Today, Avfuel touches virtually every aspect of the aviation industry with its innovative lineup of programs and solutions and through various subsidiary corporations. Avfuel currently serves more than 5,500 aviation customers at more than 3,000 worldwide locations and supplies fuel to six major aviation consumer groups: fixed-base operators (FBOs), corporate flight departments, airlines, helicopter operators, cargo haulers and the military. Avfuel subsidiaries include Avtank, which designs, engineers, and manufactures fuel storage systems and refueling equipment; Avlease, which provides management and leasing of aviation refueling equipment; Avsurance, an aviation insurance agency capable of procuring a variety of coverages for pilots, airports, equipment manufacturers, distributors and related facilities; and Avplan, a full-service flight-planning and trip-support company. Mr. Sincock continues to focus on further international expansion with the goal of realizing his vision to build a company that drives the connections of people, business and culture. The passion for aviation that led Mr. Sincock to purchase Avfuel is evident through his continued devotion to the company’s success as well as through his advocacy efforts. He has served on the boards of several prominent industry organizations, including the National Business Aviation Association (NBAA) and the General Aviation Manufacturers Association’s (GAMA), among others. Past positions include seats on the Pride Refining Inc Board of Directors (PRF: NYSE) and Duncan Aviation Board of Advisors. He is a member of the World Presidents’ Organization (WPO), an international organization fostering educational development and networking opportunities for company leaders. He has also been an active participant in the National Air Transportation Association (NATA), the Experimental Aircraft Association (EAA), the Aircraft Owners and Pilots Association (AOPA) and more. Additionally, Mr. Sincock is a pilot with an ATP rating and frequently pilots the company’s Cessna Citation XLS+. Mr. Sincock graduated from the University of Michigan and continues to reside in Ann Arbor with his wife, Sue. The Sincock’s philanthropic efforts extend well beyond the aviation community; they are also staunch supporters of organizations for health care and education. https://www.transhumancapital.com/portfolio daily 0.75 2024-12-11 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1621615363571-3Q4FM7V7992IE0CODU53/Bond+Biosciences+Logo.jpg Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589216542339-9J3FXQGG7T7LV1AKI0A2/Investments-02.jpg Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/348c60b0-d515-43f7-8630-edb1ca21f1aa/Dvant Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/008e6f23-e52c-45e7-a459-46d31caeed56/whiteArtboard+3.png Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/4c3113fc-3f35-40ec-b6d7-d994b9b6b1f3/whiteArtboard+4.png Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/70bfc8db-9b95-4620-88e3-bb7eded7f3e6/whiteArtboard+7.png Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/eec419d9-5034-48c5-bd2b-1789fc64ac6c/whiteArtboard+6+copy+4.png Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/0a929fd4-5cad-4a60-819c-4feffe6a587e/SanaHealth.png Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/0b271eca-3d7c-4fb3-9e03-3e91004678a5/whiteArtboard+6.png Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1589555346029-UVJ7BYEKCQ4Q29HBJQOZ/Investments-08.jpg Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/d6a32768-2eac-4a84-93ce-f5ea13c916bc/whiteArtboard+1.png Portfolio https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/f8acdf41-74f6-498e-aab9-da659b8206d1/whiteArtboard+2.png Portfolio https://www.transhumancapital.com/dr-miller-1 daily 0.75 2020-08-28 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1598634859410-GEB20PNYK9YEJ6VQ5A3R/RadOncolHds13d1%28116%29.JPG Mukesh Nyati - Mukesh K. Nyati, Ph. D. Associate Professor in Radiation Oncology, University of Michigan https://www.transhumancapital.com/vincent-alessi daily 0.75 2020-08-28 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1598638853469-VXR61F8NMW5T8EXBWA02/IMG-8055.jpg Vincent Alessi - Vincent A. Alessi Associate Director & Head of Strategic Information, Interoperability Institute Mr. Alessi is an award-winning inventor and technology commercialization expert with over 13 years of hands-experience building disruptive businesses through leveraging new-to-world technical platforms. Educated at Oberlin college with visiting academic fellowships at Harvard Medical School and Rockefeller University, he has served in the Departments of Defense and Energy. Past private ventures include the Aquaro Diagnostics Inc, Covaron Advanced Materials Inc, and Science Bounty Systems. His private sector work has led him to win/receive the MIT SAE Innovation of the year, Forbes 30 under 30 (2016, Industry), Schusterman Foundation Fellowship, the Materials Connexion (Steelcase) Material of the year, Walmart’s global winner for ‘better living though innovation’, Accelerate Michigan Innovation Competition, the Leigh Steinberg Foundation Brain Health Awareness Award, and others. He currently holds 17 patents, with 11 currently pending, principally within the diagnostics automation, predictive modeling, and advanced materials spaces. His current research focus is in multi-tiered computational modeling of physiological systems and the epigenetics of the Central Nervous System. https://www.transhumancapital.com/dr-miller daily 0.75 2021-05-21 https://images.squarespace-cdn.com/content/v1/5eb83469d76c927daea7f229/1598638818627-9Y9T3BBRM46XE71RQ75Z/DavidMiller Dr Miller - Dr. David Miller President of The University of Michigan Health System As President of the University of Michigan Health System, David Miller provides strategic and operational leadership for the clinical enterprise of Michigan Medicine. Prior to this role, Miller was the chief clinical officer for University Hospital and the Frankel Cardiovascular Center since 2018. Miller also was named executive vice dean of clinical affairs for the Medical School, in which he will work collaboratively with leadership from the Medical School to ensure that the clinical and medical education missions are aligned. Dr. Miller also serves as Director of the Michigan Urological Surgery Improvement Collaborative (MUSIC). Funded by Blue Cross Blue Shield of Michigan (BCBSM), MUSIC is a consortium of more than 40 urology practices aiming to improve the quality and cost‐efficiency of prostate cancer care in the state of Michigan. Dr. Miller has a broad background in health services research, including substantial experience using claims data and formal training in the advanced statistical methods used in observational data analyses. With longitudinal funding from the Agency for Healthcare Research & Quality and the National Cancer Institute, Dr. Miller's empirical research agenda focuses on comparative effectiveness research, physician‐led collaborative quality improvement, and understanding the relationship between physician organizations, integrated delivery systems, and the quality and cost of specialty care. https://www.transhumancapital.com/commercial daily 0.75 2025-04-23 https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288428308-36UTNA7X6PS0D2GJ3FY2/Stocksy_txp9c995bd1cMI100_Large_1188910.jpg Commercial Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288456336-QJYUC6S73WST51N9AG41/Stocksy_txp9c995bd1cMI100_Large_1192032.jpg Commercial Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288477477-QLUO3IOZLD0K2XGFTKT0/Stocksy_txp9c995bd1cMI100_Large_1192030.jpg Commercial Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288443993-70R8RACJ1HQJFH5BHF2R/Stocksy_txp9c995bd1cMI100_Large_1183959.jpg Commercial Design https://www.transhumancapital.com/residential daily 0.75 2025-04-23 https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288176661-C90TXFM4VNJFRC4H8YRW/Stocksy_txp9c995bd1cMI100_Large_1192028.jpg Residential Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288146199-DA9XREUMWRMKI6GQ5QVH/Stocksy_txp9c995bd1cMI100_Large_1183996.jpg Residential Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288521108-71L8CT3BCUQJ7050OMJ2/Stocksy_txp9c995bd1cMI100_Large_1184005.jpg Residential Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288141454-7MP0J8XLVB4BO0HDFIKZ/Stocksy_txp9c995bd1cMI100_Large_1184002.jpg Residential Design https://www.transhumancapital.com/experiential daily 0.75 2025-04-23 https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1558471325414-WU05TRG9JWV0E62OAV83/download+copy+2.jpeg Experiential Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288303310-TTJEIL1U469UY7OCHUMY/Stocksy_txp9c995bd1cMI100_Large_1192042.jpg Experiential Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288335378-1RLP8C2OBC0QXC2Q0QA3/Stocksy_txp9c995bd1cMI100_Large_1192029.jpg Experiential Design https://images.squarespace-cdn.com/content/v1/5ce2e1b47977970001d9545e/1560288373735-NRNSJ40PIZ23YJQJI5CV/Stocksy_txp9c995bd1cMI100_Large_1183977.jpg Experiential Design